These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27291482)

  • 21. Scintigraphy in prediction of the salivary gland function after gland-sparing intensity modulated radiation therapy for head and neck cancer.
    Tenhunen M; Collan J; Kouri M; Kangasmäki A; Heikkonen J; Kairemo K; Mäkitie A; Joensuu H; Saarilahti K
    Radiother Oncol; 2008 May; 87(2):260-7. PubMed ID: 18329118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control.
    Chajon E; Lafond C; Louvel G; Castelli J; Williaume D; Henry O; Jégoux F; Vauléon E; Manens JP; Le Prisé E; de Crevoisier R
    Radiat Oncol; 2013 May; 8():132. PubMed ID: 23721062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
    Rudat V; Münter M; Rades D; Grötz KA; Bajrovic A; Haberkorn U; Brenner W; Debus J
    Radiother Oncol; 2008 Oct; 89(1):71-80. PubMed ID: 18707782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
    Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
    Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
    Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up.
    Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J
    Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
    Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensity-modulated radiation therapy and xerostomia.
    Chambers MS; Weber RS; Garden AS
    J Calif Dent Assoc; 2006 Sep; 34(9):743-8. PubMed ID: 17022299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of submandibular salivary gland transfer and intensity-modulated radiotherapy to reduce dryness of mouth (xerostomia) in patients with head and neck cancer.
    Scrimger RA; Seikaly H; Vos LJ; Harris J; O'Connell D; Ghosh S; Debenham B; Jha N
    Head Neck; 2018 Nov; 40(11):2353-2361. PubMed ID: 30175876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal assessment of parotid function in patients receiving tomotherapy for head-and-neck cancer.
    Voordeckers M; Everaert H; Tournel K; Verellen D; Baron I; Van Esch G; Vanhove C; Storme G
    Strahlenther Onkol; 2008 Aug; 184(8):400-5. PubMed ID: 18956516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy.
    Henson BS; Inglehart MR; Eisbruch A; Ship JA
    Oral Oncol; 2001 Jan; 37(1):84-93. PubMed ID: 11120488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy for head and neck cancer?
    Nevens D; Nuyts S
    Br J Radiol; 2017 Dec; 90(1080):20170596. PubMed ID: 28972794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intensity-modulated radiotherapy for head and neck cancer. Dose constraint for salivary gland and mandible].
    Pointreau Y; Lizée T; Bensadoun RJ; Boisselier P; Racadot S; Thariat J; Graff P
    Cancer Radiother; 2016 Oct; 20(6-7):445-51. PubMed ID: 27614524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing.
    Eisbruch A; Marsh LH; Dawson LA; Bradford CR; Teknos TN; Chepeha DB; Worden FP; Urba S; Lin A; Schipper MJ; Wolf GT
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):28-42. PubMed ID: 15093896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Usefulness of pilocarpine in the prevention of xerostomia in patients with head and neck cancer treated with radiotherapy. Assessment with gammagraphy and salivary flow].
    Fuertes Cabero S; Setoain Perego X; Rovirosa Casino A; Mateos Fernández JJ; Fuster Pelfort D; Ferre Jorge J; Navalpotro Yagüe V; Paredes Barranco P; Ortín Pérez J; Muxí Pradas A; Pons Pons F
    Rev Esp Med Nucl; 2004; 23(4):259-66. PubMed ID: 15207210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parotid-gland-sparing 3D conformal radiotherapy in patients with bilateral radiotherapy of the head and neck region--results in clinical practice.
    Hey J; Setz J; Gerlach R; Janich M; Sehlleier S; Schaller HG; Gernhardt CR; Kuhnt T
    Oral Oncol; 2009 Feb; 45(2):e11-7. PubMed ID: 18621572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of submandibular gland excision on salivary gland function in head and neck cancer patients.
    Jaguar GC; Lima EN; Kowalski LP; Pellizon AC; Carvalho AL; Alves FA
    Oral Oncol; 2010 May; 46(5):349-54. PubMed ID: 20227906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Xerostomia in patients treated for oropharyngeal carcinoma: comparing linear accelerator-based intensity-modulated radiation therapy with helical tomotherapy.
    Fortin I; Fortin B; Lambert L; Clavel S; Alizadeh M; Filion EJ; Soulières D; Bélair M; Guertin L; Nguyen-Tan PF
    Head Neck; 2014 Sep; 36(9):1343-8. PubMed ID: 24038408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Helical tomotherapy for head and neck squamous cell carcinoma: dosimetric comparison with linear accelerator-based step-and-shoot IMRT.
    Murthy V; Master Z; Gupta T; Ghosh-Laskar S; Budrukkar A; Phurailatpam R; Agarwal J
    J Cancer Res Ther; 2010; 6(2):194-8. PubMed ID: 20622367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.